Document Detail

Active Surveillance for Prostate Cancer: Overview and Update.
MedLine Citation:
PMID:  23318986     Owner:  NLM     Status:  Publisher    
OPINION STATEMENT: Low-risk prostate cancer: How I would treat it?Overtreatment of many conditions diagnosed by screening has become increasingly recognized as a contemporary malady associated with modern medicine's efforts at earlier detection. The diagnosis of low-grade prostate cancer clearly qualifies as an example of potential overdiagnosis and overtreatment. Active surveillance for low-risk prostate cancer is an attempt to reduce the overtreatment of the disease. The approach involves initial expectant management rather than immediate therapy. Curative treatment is deferred while the patient is monitored and offered for evidence of risk reclassification to a more aggressive form of the disease. The basis for this approach is substantial evidence confirming the long natural history of most prostate cancers. The objective is to balance the risks of overtreatment and associated adverse quality of life effects, against the risk of progression of disease and a missed opportunity for curative therapy. Low-risk prostate cancer is more accurately viewed as one of several risk factors for the patient harboring higher-grade disease, rather than a life-threatening condition. This approach is similar to that taken historically for so-called precancerous conditions, such as PIN or ASAP, where patients were managed with close follow-up but without radical intervention unless clear evidence of more aggressive disease is identified. Active surveillance is increasingly viewed as the management of choice for patients with very low-risk (low-grade, low-volume prostate cancer) and low-risk (low-grade but higher volume) disease.
Laurence Klotz
Related Documents :
24643216 - Respecting cancer committee members as volunteers: tools for the cancer registrar.
23868476 - Clinical outcomes from the cdc's colorectal cancer screening demonstration program.
23034146 - Association between ambient ultraviolet radiation and risk of epithelial ovarian cancer.
23772886 - Characterizing biased cancer-related cognitive processing: relationships with brca1/2 g...
16472776 - Identification of integrin alpha1 as an interacting protein of protein tyrosine phospha...
21528086 - A case-control study on the relationship between salt intake and salty taste and risk o...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-15
Journal Detail:
Title:  Current treatment options in oncology     Volume:  -     ISSN:  1534-6277     ISO Abbreviation:  Curr Treat Options Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100900946     Medline TA:  Curr Treat Options Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave MG 408, Toronto, M4N 3M5, Ontario, Canada,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Next Document:  What can be learned from a chaotic cancer model?